eXpert International Oncology MEeting

APPLICABILITY OF WESTERN GUIDELINES IN LOW- AND MIDDLE-INCOME COUNTRIES (LMICs) 

Welcome Venue  

Y Belkacemi (France), A Bounedjar (Algeria), J Gligorov (France), 

R Samlali (Morocco), S Turkan (Turkey)

eXpert Advice in complex cases 

Interactive session

MAIN ROOM

Locally Advanced Breast Cancer (BC) Session 

Moderators

P Tsoutsou (Switzerland) -  M AL Foheidi (SA) - H Errihani (Morocco)

Keynote 1: Molecular classifications of BC for practice : update and upcoming

N Radosevic (France) 

Locally advanced breast cancer interactive patient case 1:

Multidisciplinary management of Triple Negative BC: neoadjuvant and adjuvant guidelines

A Awada (Belgium), E Gazioglu (Turkey), Case presentation by: K Debbi  (France)

Locally advanced breast cancer interactive patient case 2:
Multidisciplinary management of Her2 positive BC: neoadjuvant and adjuvant guidelines

K El Hassani (Morocco), MP Chauvet (France), Case presentation by: M Bojovic (Serbia)

Locally advanced breast cancer interactive patient case 3:
Multidisciplinary management of HR+/Her2- non-menopausal BC:  standards and options

A Taghian (USA), G Gligorov (France), Case presentation by: B Al Qadi (SA)

Round table discussion and take home messages for daily practice

P Tsoutsou (Switzerland), M AL- Foheidi (SA), H Errihani (Morocco)

Coffee break

 MAIN ROOM

Cervix Cancer Session

Moderators

ER Ozlem (Turkey) - O Ivanov (Serbia) - Y Bensouda  (Morocco)

Cervix interactive patient case 1:
Multidisciplinary management of stage IB-IIA cervix cancer

K Kerrou (France), M Güngor (Turkey), Case presentation by: C Atahan (Turkey)

Cervix interactive patient case 2:
Multidisciplinary management of stage IIIB-IV cervix cancer

C Chargari (France),  C Taskiran (Turkey), Case presentation by :  O Nouri (Tunisia)

Round table discussion and take home messages for daily practice

O Ivanov (Serbia), Er Ozlem (Turkey), Y Bensouda (Morocco)

Keynote 2: Cervix cancer management: surgery and metabolic imaging for optimal staging?

K Kerrou (France)

MAIN ROOM

Opening ceremony in memoriam to A Kuten 

By M. Bolla and F. Benna by H. Boussen

A Bounedjar (Algeria) - J Gligorov (France) - R Samlali (Morocco)

Arome Projects and publication strategy and Partnership (ATTICA PROJECT: Use of IT communication technologies and dATa proTection In onCology hospitAls)

J Malicki (Poland), D Tesanovic (Serbia) M. Mocydlarz-Adamcewicz (Poland)

CLOSING REMARKS

Y Belkacemi (France)

MEDITERRANEAN SCIENTIFIC SOCIETIES EXCHANGES DINNER

eXpert International Oncology MEeting

Expert Opinions in controversies

MAIN ROOM

Intermediate and high risk Prostate Cancer (PCa)

Moderators

M Oukkal (Algeria) - Y Belkacemi (France) - B Atalar (Turkey)

Keynote 3: Intermediate and high risk PCa : Past and Current challenges for optimal combined radio-homonotherapy

M Bolla (France)

Surgery for high risk PCa is a validated option?
In favor for multimodal strategy including surgery
In favor for combined radiohormonotherapy without surgery

B Argun  (Turkey ), F Geara (UAE)

Combined  hormonotherapy and radiation is the standard for ALL intermediate risk PCa:
In favor                                                                                                                              
Against

D Tesanovic (Serbia), C Obek (Turkey)

Management of oligometastatic castrate-sensitive prostate cancer (mCSPCa):
In favor to use the systemic “triplet” protocol early       
In favor to standard hormonotherapy and stereotactic radiation

L Popovic (Serbia), M Krengli (Italy)

Round table discussion and take home messages for daily practice

M Oukkal (Algeria), Y Belkacemi (France), B Atalar (Turkey)

Coffee break

Metastatic castration sensitive/resistant Prostate Cancer (PCa): Therapeutic challenges

Moderators

F Geara (UAE) - D Mukherji (UAE) - A Dib (Algeria)

Keynote 4: How to optimize local therapy  in the new era of hormone therapy for synchronous mCSPCa ?

E Ozyar (Turkey)

Interactive patient case 1: Personalizing the sequence of local and systemic therapy in mCSPCa

G Demir (Turkey), H Boussen (Tunisia), Case presentation by FZ Bellefkih (Morocco)

Interactive patient case 2: Role of sequential of systemic and local therapies in mCRPCa

K Oualla (Morocco), M Ozsahin (Switzerland), Case presentation by S Zaidi (Algeria)

Keynote 5 : How to personalize in 2024 systemic therapy in mCRPCa  ? 

D Mukherji (UAE)

Round table discussion and take home messages for daily practice

F Geara (UAE),  D Mukherji (UAE)

Meet the Expert Sponsored Symposium 

(Sponsored by MSD): 

Immune Check point inhibition in early and locally advanced cancers: example of breast and cervix.

Experience from triple negative breast cancer

by J Gligorov (France)

ICI in combination with chemoradiation in LACC 

by K Oualla (Morocco) 

Lunch break

eXpert International Oncology MEeting

eXpert Review of the international
Guidelines for Locallay Advanced Diseases

eXIOME WORKING PARTIES

14:00-15:30:

MAIN ROOM

Meet Breast Cancer experts: International Guidelines 

Discussion for locally advanced breast cancers 

Coordination: 

Y Belkacemi (France), A Bounedjar (Algeria), 

S Turkan (Turkey)

 Report by A Awada (Belgium), J Gligorov (France)

• Loco-regional treatments in cN0 and cN1 BC: Axilla management after neoadjuvant therapy ?

     MP Chauvet (France), Y Bolukbasi (Turkey)

•  Adjuvant therapy in HR positive, HER2 negative BC : wich adjuvant systemic therapy in residual disease after neoadjuvant therapy?

     N Berrada (Morocco), J Gligorov (France)

• Adjuvant therapy in young women with HR positive, HER2 negative BC: type and duration of endocrine therapy?

     H Boussen (Tunisia),  H Errihani (Morocco), A Awada (Belgium)

• Loco-regional treatments in cN0 and cN1 BC : radiation therapy volumes according to the response after neoadjuvant therapy ?

     P Tsoutsou (Switzerland), A Taghian (USA)

ROOM 2

Meet Cervix Cancer experts: International Guidelines 

Discussion for locally advanced cervix cancers

Coordination: 

R Samlali (Morocco), S Kanoun (Tunisia), C Taskiran (Turkey)

Report by C Chargari (France), D Tesanovic (Serbia) 

• Imaging and AI for staging

     G Dagoglu Kartal (Turkey)

• Combined radiochemotherapy and surgery indications

     C Chargari (France), M Oukkal (Algeria)

• External beam radiotherapy and brachytherapy

    O Ivanov (Serbia), I Flandin (France), S Sahraoui (Morocco)

• Follow-up: timing, tools, duration

     D Tesanovic (Serbia),  ER Ozlem (Turkey), FZ Bellefkih (Morocco)

 ROOM 1

Meet Prostate Cancer experts: International Guidelines 

Discussion for mCSPCa and mCRPCa
Coordination:  

L Popovic (Serbia), F Geara (UAE), F Guedea (Spain)

Report by F Geara (UAE), D Mukherji (UAE)

• Local therapies in oligometastatic situations: how to optimize the sequence?

     E Ozyar (Turkey), C Obek (Turkey), M Krengli (Italy)

• Management of synchronous mCSPCa in the new era of 2nd generation of hormone therapy

     F Guedea (Spain), K Oualla (Morocco), D Geara (UAE)

• New generation of hormone therapy and chemotherapy: role and sequence in mCRPCa?

     L Popovic (Serbia), P Hurmuz (Turkey), K Debbi (France)

• Management of BRCA mutated patients: from labs to patients

    D Mukherji (UAE),  B El Khannoussi (Morocco), N Radosevic (France)

Coffee break

MAIN ROOM

Meet the Expert Plenary Conference 

(Sponsored by JANSSEN): 

The role of Erleada in non-metastatic CRPC and mHSPC: optimal start, saving other options for future! 

Moderators

E Ozyar (Turkey)

By A Hassan Abdelaziz (Egypt)

17:00-18:00 : 

MAIN ROOM

Meet the Expert Plenary Conference 

(Sponsored by ELEKTA): 

How MRI 1.5T  integrated in a linear accelerator can revolutionize modern radiation therapy? 

Moderators

S Turkan (Turkey), Y Belkacemi (France)

By E Merdan Fayda (Turkey)

MEET THE EXPERT DINNER (Sponsored by ELEKTA)

eXpert International Oncology MEeting

eXpert Plenary session

eXIOM 24 post-meeting Highlights & Working Parties Report:

"From minimal requirements to optimal acceptable guidelines in LMICs"

 Moderators

M AL-Foheidi (SA) -  A Bounedjar (Algeria) -  J Malicki (Poland-RPOR)

MAIN ROOM

Locally Advanced Breast Cancer (adjuvant and neoadjuvant) and endocrine therapy for young patients with breast cancer

A Awada (Belgium), J Gligorov (France)

Locally Advanced Cervix Cancer

C Chargari (France), D Tesanovic (Serbia)

Local and systemic therapy for High risk Prostate Cancer 

F Geara (UAE), D Murkherji (UAE)

Metastatic Castration Sensitive and Resistant Prostate Cancer

L Popovic (Serbia), K Oualla (Morocco)

Closing remarks

ALL

Coffee breack

MAIN ROOM

Meet the Expert Sponsored Symposium 

(VARIAN - A SIEMENS HEALTHINEERS COMPANY): 

Realizing modern, high-quality radiotherapy in LMICs 

By T Wilson (Switzerland) 

MAIN ROOM

eXpert Poster Discussion with 

AROME Junior Network

Moderators

E Ozyar (Turkey)  -  O Ivanov (Serbia) - N Berrada (Morocco)

Mechanism of PARP1/TCF7L2 axis mediated aerobic glycolysis in regulating the metastasis of triple-negative BC

Q Lei (China) 

Late toxicity and cosmetic outcome of the ultra-hypofractionated radiotherapy of breast cancer

N Aničić (Serbia)

Factors associated with acute toxicity of moderately hypofractioned ratherapy in breast cancer: preliminary results of a prospective cohort study

MB Ba (Senegal)

When an external fixator is used in cervical cancer brachytherapy, can packing be avoided? The rationale of vaginal gauze packing on the rectum and bladder

U Diremsizoglu (Turkey)

Cervical cancer in ederly women: patterns of care in a radiotherapy department in a country with high prevalence

W Hassani (Morocco)

Evaluation of the efficacy and safety of paclitaxel, carboplatin and bevacizumab combination followed by maintenance bevacizumab therapy in recurrent, persistent or metastatic uterine cervical cancer

H Idir (Algeria)

The Turkish Validation of the Expanded Prostate Cancer Index Composite (EPIC) in Prostate Cancer Patients.

B. Tilky (Turkey)

Sexuality and Prostate Cancer

S Nejjari (Morocco), M Alem (Morocco)

Long-term results of cervical cancer patients < 45 Years. A tertiary-center experience 

E Demir (Turkey)

Online Adaptive Stereotactic Body Radiotherapy with MR Guidance in the treatment of prostate cancer patients. A Hacettepe University Study

T.Z Mustafayev (Turkey), S Mutaf (Turkey)

Closing remarks

Y Belkacemi (France), A Bounedjar (Algeria), J Gligorov (France), R Samlali (Morocco), S Turkan (Turkey)